Nanobiotix Unveils Preclinical Proof-of-Concept for Curadigm Nanoprimer in Cancer Treatment
Nanobiotix SA has announced promising preclinical results for its Curadigm Nanoprimer platform in cancer treatment. The in vivo data, presented at the 2025 PODD conference, establish proof-of-concept for the platform's potential applications. The company has also filed four new patent applications to expand its intellectual property portfolio. This news was originally published by Nanobiotix SA via GlobeNewswire on November 13, 2025.
Nanobiotix SA has announced new advancements for its Curadigm Nanoprimer platform, highlighting promising preclinical research results. In vivo pre-clinical data evaluating the Nanoprimer in combination with therapeutic vaccines were presented at the 2025 Partnership Opportunities in Drug Delivery (PODD) conference. These findings establish in vivo proof-of-concept for the platform’s potential applications in cancer treatment and beyond. The company has also filed four new patent applications to expand the intellectual property portfolio supporting both its internal product pipeline and ongoing external collaborations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanobiotix SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575520-en) on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
